Evasión Tumoral y Nuevas Dianas
Harvard Medical School
Boston, Estados UnidosPublicaciones en colaboración con investigadores/as de Harvard Medical School (4)
2023
-
Leukemia-intrinsic determinants of CAR-T response revealed by iterative in vivo genome-wide CRISPR screening
Nature Communications, Vol. 14, Núm. 1
2022
-
Mutant IDH Inhibits IFNg–TET2 Signaling to Promote Immunoevasion and Tumor Maintenance in Cholangiocarcinoma
Cancer Discovery, Vol. 12, Núm. 3, pp. 812-835
2021
-
In vivo screens using a selective CRISPR antigen removal lentiviral vector system reveal immune dependencies in renal cell carcinoma
Immunity, Vol. 54, Núm. 3, pp. 571-585.e6
2019
-
Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade
Nature, Vol. 565, Núm. 7737, pp. 43-48